



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
20.04.2022 Bulletin 2022/16

(45) Date of publication and mention
of the grant of the patent:
19.01.2022 Bulletin 2022/03

(21) Application number: **16837634.1**

(22) Date of filing: **15.08.2016**

(51) International Patent Classification (IPC):
A61K 47/50 ^(2017.01) **A61K 47/06** ^(2006.01)
A61K 31/5383 ^(2006.01) **A61K 31/426** ^(2006.01)
A61P 35/00 ^(2006.01) **A61K 47/68** ^(2017.01)
C07K 16/32 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
A61K 47/6803; A61K 47/6855; A61K 47/6869;
A61K 47/6889; A61P 35/00; C07K 16/32

(86) International application number:
PCT/US2016/046987

(87) International publication number:
WO 2017/031034 (23.02.2017 Gazette 2017/08)

(54) **COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME**

KOVALENTE LINKER IN ANTIKÖRPER-WIRKSTOFF-KONJUGATEN UND VERFAHREN ZUR HERSTELLUNG UND VERWENDUNG DAVON

LIEURS COVALENTS DANS DES CONJUGUÉS ANTICORPS-MÉDICAMENT ET LEURS PROCÉDÉS DE PRODUCTION ET D'UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **14.08.2015 US 201562205121 P**

(43) Date of publication of application:
20.06.2018 Bulletin 2018/25

(60) Divisional application:
21206552.8 / 3 981 433

(73) Proprietor: **RemeGen Biosciences, Inc.**
Fremont, CA 94538 (US)

(72) Inventors:
• **HUANG, Chang Jiang**
Los Angeles, CA 90064 (US)
• **FANG, Jianmin**
Palo Alto, CA 94306 (US)
• **YE, Hui**
Shandong 264006 (CN)

• **ZHANG, Lezhi**
Shandong 264006 (CN)

(74) Representative: **Icosa**
83 avenue Denfert-Rochereau
75014 Paris (FR)

(56) References cited:
WO-A1-2013/085925 WO-A1-2013/085925
WO-A1-2015/004400 WO-A2-2015/187596
WO-A2-2016/064749 CN-A- 103 933 575
CN-A- 103 933 575 US-A1- 2003 215 395

• **YAO, X. ET AL.: 'A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity' BREAST CANCER RESEARCH AND TREATMENT vol. 153, no. 1, 08 August 2015, pages 123 - 133, XP055370764**
• **QIN, M. ET AL.: 'Click conjugation of peptide to hydrogel nanoparticles for tumor-targeted drug delivery' BIOMACROMOLECULES vol. 15, no. 10, 13 October 2014, pages 3728 - 3734, XP055370767**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- J. Guenther ET AL: "Synthesis, Immobilization, MAS and HR-MAS NMR of a New Chelate Phosphine Linker System, and Catalysis by Rhodium Adducts Thereof", *Advanced Synthesis & Catalysis*, vol. 353, no. 2-3, 11 February 2011 (2011-02-11), pages 443-460, XP055681607, DE ISSN: 1615-4150, DOI: 10.1002/adsc.201000585